IL-21 Critically Regulates Immunoglobulin Production
Posted Apr 30 2004 5:00pm
Description of Invention: The invention includes a mouse in which the IL-21 receptor gene is disrupted by homologous recombination, the disruption being sufficient to prevent expression of the IL-21 receptor and thus to inhibit the action of IL-21. The invention also includes a mouse in which both the IL-21 receptor gene and the IL-4 gene are simultaneously disrupted in fashions being sufficient to inhibit the action of IL-21 and the production of IL-4. In a homozygous state, these mutations produce a mouse that has diminished B cell function.
This invention also relates to the use of agents that inhibit the interaction of IL-21 with the IL-21 receptor to modulate an immune response. This invention may be used to alter B cell activity, to treat a subject with Job's disorder, to treat an allergic reaction in a subject, or prevent an allergic reaction in a subject,
Portfolios: Internal Medicine Internal Medicine - Therapeutics Internal Medicine - Research Materials
For Additional Information Please Contact: Jennifer Wong NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: wongje@mail.nih.gov Phone: 301-435-4633 Fax: 301-402-0220
Description of Invention:
The invention includes a mouse in which the IL-21 receptor gene is disrupted by homologous recombination, the disruption being sufficient to prevent expression of the IL-21 receptor and thus to inhibit the action of IL-21. The invention also includes a mouse in which both the IL-21 receptor gene and the IL-4 gene are simultaneously disrupted in fashions being sufficient to inhibit the action of IL-21 and the production of IL-4. In a homozygous state, these mutations produce a mouse that has diminished B cell function.
This invention also relates to the use of agents that inhibit the interaction of IL-21 with the IL-21 receptor to modulate an immune response. This invention may be used to alter B cell activity, to treat a subject with Job's disorder, to treat an allergic reaction in a subject, or prevent an allergic reaction in a subject,
Inventors:
Warren J Leonard (NHLBI)
Katsutoshi Ozaki (NHLBI)
Rosanne Spolski (NHLBI)
Patent Status:
HHS, Reference No. E-211-2002/0
HHS, Reference No. E-211-2002/1
US, , Patent No. 7,332,645, Issued 19 Feb 2008
US, Application No. 11/958,540 filed 18 Dec 2007
Portfolios:
Internal Medicine
Internal Medicine - Therapeutics
Internal Medicine - Research Materials
For Additional Information Please Contact:
Jennifer Wong
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: wongje@mail.nih.gov
Phone: 301-435-4633
Fax: 301-402-0220
Ref No: 843
Updated: 05/2004